Patents Represented by Attorney, Agent or Law Firm Ron K. Levy
  • Osteoprotegerin
    Patent number: 6015938
    Abstract: The present invention discloses a novel secreted polypeptide, termed Osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding Osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind Osteoprotegerin, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis.
    Type: Grant
    Filed: November 18, 1997
    Date of Patent: January 18, 2000
    Assignee: Amgen Inc.
    Inventors: William J. Boyle, David L. Lacey, Frank J. Calzone, Ming-Shi Chang
  • Implantable device containing GDNF secreting cells for treating nerve damage and methods of use
    Patent number: 6015572
    Abstract: A novel neurotrophic factor referred to as glial cell line-derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector, and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process. An implantable device containing recombinant GDNF secreting cells encapsulated in a semipermeable membrane may be used to treat nerve damage in patients suffering from disorders such as Parkinson's disease.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: January 18, 2000
    Assignee: Amgen Inc.
    Inventors: Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, Susan Bektesh
  • Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
    Patent number: 6013253
    Abstract: The present invention encompasses methods for preventing and treating multiple sclerosis by administering to patients in need thereof a therapeutically effective amount of IFN-con in combination with IL-1ra.
    Type: Grant
    Filed: August 15, 1997
    Date of Patent: January 11, 2000
    Assignee: Amgen, Inc.
    Inventors: David Martin, Norman L. Fischer
  • Method for purifying keratinocyte growth factors
    Patent number: 6008328
    Abstract: The present invention concerns the purification of keratinocyte growth factors.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 28, 1999
    Assignee: Amgen Inc.
    Inventors: Eric W. Hsu, William C. Kenney, Tim Tressel
  • Polynucleotides encoding hepatocyte-specific members of the FGF family
    Patent number: 5998170
    Abstract: Nucleic acid molecules are described which are useful in vectors, transformed or transfected host cells, and methods for the recombinant expression of hepatocyte growth-specific polypeptide members of the FGF family.
    Type: Grant
    Filed: October 3, 1997
    Date of Patent: December 7, 1999
    Assignee: Amgen Inc.
    Inventors: Tsutomu Arakawa, Dimitry Michael Danilenko, Nobuyuki Itoh, Francis Hall Martin
  • N-terminally chemically modified protein compositions and methods
    Patent number: 5985265
    Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.
    Type: Grant
    Filed: June 20, 1997
    Date of Patent: November 16, 1999
    Assignee: Amgen Inc.
    Inventors: Olaf B. Kinstler, Nancy E. Gabriel, Christine E. Farrar, Randolph B. DePrince
  • Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
    Patent number: 5980884
    Abstract: Methods for the retreatment, using a therapeutically effective amount of interferon consensus, of patients with HCV who exhibit serum ALT values above the upper limit of normal after previous treatment with interferon.
    Type: Grant
    Filed: February 5, 1996
    Date of Patent: November 9, 1999
    Assignee: Amgen, Inc.
    Inventors: Larry Blatt, Michael Klein
  • EPH-like receptor protein tyrosine kinases
    Patent number: 5981245
    Abstract: Four novel members of the EPH sub-family of receptor protein tyrosine kinases are disclosed. Nucleic acid sequences encoding receptor proteins, recombinant plasmids and host cells for expression, and methods of producing and using such receptors are also disclosed.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: November 9, 1999
    Assignee: Amgen Inc.
    Inventors: Gary M. Fox, Andrew A. Welcher, Shuqian Jing
  • Genes encoding telomerase protein 1
    Patent number: 5981707
    Abstract: Disclosed are nucleic acid molecules encoding polypeptides that specifically bind telomerase RNA. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.
    Type: Grant
    Filed: April 15, 1998
    Date of Patent: November 9, 1999
    Assignees: Amgen Inc., Amgen Canada Inc.
    Inventors: Lea Anne Harrington, Murray O. Robinson
  • Nucleic acids encoding EPH-like receptor protein tyrosine kinases
    Patent number: 5981246
    Abstract: Four novel members of the EPH sub-family of receptor protein tyrosine kinases are disclosed. Nucleic acid sequences encoding receptor proteins, recombinant plasmids and host cells for expression, and methods of producing and using such receptors are also disclosed.
    Type: Grant
    Filed: August 21, 1996
    Date of Patent: November 9, 1999
    Assignee: Amgen Inc.
    Inventors: Gary M. Fox, Andrew A. Welcher, Shuqian Jing
  • Cyclin E genes and proteins
    Patent number: 5973119
    Abstract: Disclosed are nucleic acid molecules encoding novel cyclin E2 polypeptides. Also disclosed are methods of preparing the nucleic acid molecules and polypeptides, and methods of using these molecules.
    Type: Grant
    Filed: June 5, 1998
    Date of Patent: October 26, 1999
    Assignee: Amgen Inc.
    Inventors: Steven Roy Coats, Michael Brian Bass, Murray O. Robinson
  • Stem cell factor formulations and methods
    Patent number: 5965522
    Abstract: The invention relates to a novel formulation of stem cell factor. The formulation contains histidine, glutamic acid, sucrose and mannitol. The formulation has a pH between 5.0 and 6.0 and has been lyophilized.
    Type: Grant
    Filed: June 29, 1998
    Date of Patent: October 12, 1999
    Assignee: Amgen Inc.
    Inventor: Susan I. Hershenson
  • Therapeutic uses of keratinocyte growth factor
    Patent number: 5965530
    Abstract: Based on extensive in vivo studies in animals, it has now been discovered that KGF stimulates proliferation, growth and differentiation in various cells of epithelial tissue, besides keratinocytes. This better understanding of the biological effects of KGF in vivo enables the use of this polypeptide as a therapeutic agent, suitably formulated in a pharmaceutical composition, for the specific treatment of disease states and medical conditions afflicting tissues and organs such as the dermal adnexae, the liver, the lung, and the gastrointestinal tract.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 12, 1999
    Assignee: Amgen Inc.
    Inventors: Glenn Francis Pierce, Regina Mae Housley, Charles Frederick Morris
  • Peptides capable of modulating inflammatory heart disease
    Patent number: 5962636
    Abstract: Disclosed are novel peptides that modulate inflammatory heart disease. Also disclosed are DNA molecules encoding the peptides, and methods of making the peptides.
    Type: Grant
    Filed: August 12, 1998
    Date of Patent: October 5, 1999
    Assignee: Amgen Canada Inc.
    Inventors: Kurt Bachmaier, Andrew John Hessel, Nickolaus Neu, Josef Martin Penninger
  • Analogs of macrophage stimulating protein
    Patent number: 5948892
    Abstract: MSP analogs which have increased heterodimer formation and enhanced biological activity compared recombinant MSP are provided. The analogs are constructed by substituting unpaired cysteine residues which may interfere with interchain disulfide bonding. DNA sequences encoding MSP analogs, vectors and host cells for the expression of MSP analogs, and pharmaceutical compositions are also provided. The analogs may be used to treat conditions treatable by MSP such as gastrointestinal or hematopoietic disorders.
    Type: Grant
    Filed: December 16, 1996
    Date of Patent: September 7, 1999
    Assignee: Amgen Inc.
    Inventor: Robert C. Wahl
  • Use of hydrophobic interaction chromatography to purify polyethylene glycols
    Patent number: 5935564
    Abstract: The present invention relates to a process for purifying polyethylene glycols (PEGs) which utilizes hydrophobic interaction chromatography (HIC) to separate the PEGs based on their size and on their end-group functionality. The purified PEGs can be used to modify biologically active molecules and improve overall production of such molecules.
    Type: Grant
    Filed: September 18, 1997
    Date of Patent: August 10, 1999
    Assignee: Amgen Inc.
    Inventor: James Ervin Seely
  • Glial cell line-derived neurotrophic factor antibody
    Patent number: 5935795
    Abstract: A novel neurotrophic factor referred to as glial cell line-derived neurotrophic factor (GDNF) has been identified and isolated from serum free growth conditioned medium of B49 glioblastoma cells. Rat and human genes encoding GDNF have been cloned and sequenced. A gene encoding GDNF has been subcloned into a vector and the vector has been used to transform a host cell in order to produce biologically active GDNF in a recombinant DNA process. Antibodies to GDNF are disclosed, as well as methods for identifying members of the GDNF family of neurotrophic factors.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: August 10, 1999
    Assignee: Amgen Inc.
    Inventors: Leu-Fen H. Lin, Franklin D. Collins, Daniel H. Doherty, Jack Lile, Susan Bektesh
  • Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
    Patent number: 5929041
    Abstract: The present invention relates generally to methods for preventing and/or treating injury or degeneration of cochlear (and vestibular) hair cells and spiral ganglion neurons (as well as vestibular neurons--Carpa's neurons) by administering glial cell line-derived neurotrophic factor (GDNF). The invention relates more specifically to methods for treating sensorineural hearing loss and vestibular disorders.
    Type: Grant
    Filed: September 13, 1996
    Date of Patent: July 27, 1999
    Assignee: Amgen Inc.
    Inventor: Ella Magal
  • Methods of purifying hematopoietic cells using an antibody to a stem cell factor receptor
    Patent number: 5922847
    Abstract: The present invention relates to monoclonal antibodies specific for a cell receptor specific for human stem cell factor (hSCF) as well as pharmaceutical compositions containing such monoclonal antibodies and uses of such monoclonal antibodies.
    Type: Grant
    Filed: June 7, 1994
    Date of Patent: July 13, 1999
    Assignee: Amgen Inc.
    Inventors: Virginia C. Broudy, Nancy Lin
  • Monoclonal antibodies to stem cell factor receptors
    Patent number: 5919911
    Abstract: The present invention relates to monoclonal antibodies specific for a cell receptor specific for human stem cell factor (hSCF) as well as pharmaceutical compositions containing such monoclonal antibodies and uses of such monoclonal antibodies.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: July 6, 1999
    Assignee: Board of Regents of the University of Washington
    Inventors: Virginia C. Broudy, Nancy Lin